Reuters logo
BRIEF-Trillium Therapeutics provides additional details on TTI-621
February 24, 2017 / 5:55 PM / 7 months ago

BRIEF-Trillium Therapeutics provides additional details on TTI-621

Feb 24 (Reuters) - Trillium Therapeutics Inc:

* Trillium Therapeutics provides additional details on TTI-621

* TTI-621’s half-life and receptor occupancy significantly increased with weekly dosing

* Additional data has clarified transient thrombocytopenia observed following TTI-621 exposure is often diminished after multiple infusions

* Weekly infusions of TTI-621 lead to a longer half-life and accumulation of circulating drug, overcoming platelet antigen sink

* “Latest results suggest that we achieved meaningful TTI-621 exposure while maintaining acceptable platelet counts”

* Additional data on TTI-621 suggests that there may be an opportunity to increase TTI-621 exposure in patients after initial dose Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below